FOR YOUR ADULT PATIENTS WITH ANEMIA OF CHRONIC KIDNEY DISEASE (CKD) ON DIALYSIS FOR AT LEAST 4 MONTHS1

FINALLY, A DIFFERENT WAY TO TREAT

with JESDUVROQ (daprodustat), the first FDA-approved oral HIF PHI1

FOR YOUR ADULT PATIENTS WITH ANEMIA OF CHRONIC KIDNEY DISEASE (CKD) ON DIALYSIS FOR AT LEAST 4 MONTHS1

FINALLY, A DIFFERENT WAY TO TREAT

with JESDUVROQ (daprodustat), the first FDA-approved oral HIF PHI1

Once daily icon

NEEDLE-FREE DOSING

Offer your appropriate patients on peritoneal dialysis and hemodialysis for at least 4 months, the option of once-daily, oral dosing.1

CONSIDER JESDUVROQ TODAY

Three people icon

JESDUVROQ EFFICACY

Comparable to ESA for change in Hb level1*

Mean treatment difference for change in Hb from baseline to EP: 0.2 g/dL (95% CI, 0.1 to 0.2)

REVIEW EFFICACY RESULTS

Heart icon

JESDUVROQ CV SAFETY

Comparable to ESA for cardiovascular outcomes1*

Time to first occurrence of MACE: HR, 0.93 (95% CI, 0.81 to 1.07)§

EXPLORE SAFETY DATA

HIF PHI, hypoxia-inducible factor-prolyl hydroxylase inhibitor.
*ESA: darbepoetin alfa for patients on peritoneal dialysis; epoetin alfa for patients on hemodialysis.
Prespecified noninferiority margin of -0.75 g/dL was met.
Defined as all-cause mortality, nonfatal myocardial infarction, or nonfatal stroke.
§Prespecified noninferiority margin of 1.25 was met.

Robust clinical trial1

The efficacy and safety of JESDUVROQ were evaluated in adults with Anemia due to CKD on dialysis for at least 4 months and receiving an ESA at the time of study entry in a randomized, sponsor-blind, active-controlled, global, event-driven clinical trial (N=2,964). Study co-primary endpoints were mean change in Hb from baseline to the EP (Weeks 28-52) and time to first adjudicated MACE, using a noninferiority comparison for JESDUVROQ to ESA for both endpoints.1

REVIEW STUDY DESIGN

ascend dialysis logo

HIF PHI: A novel MOA for adult patients with Anemia of CKD on dialysis for at least 4 months1-3

Oral JESDUVROQ activates the body’s natural adaptive response to hypoxia and stimulates the production of endogenous EPO.1,3

JESDUVROQ mechanism of action infographic
JESDUVROQ mechanism of action infographic

Take a deeper look at the MOA

Watch all 3 chapters of the MOA video, including an overview of the HIF pathway.

SEE JESDUVROQ IN ACTION

ASCEND-D, Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis; CI, confidence interval; CV, cardiovascular; EP, Evaluation Period; EPO, erythropoietin; ESA, erythropoiesis-stimulating agent; Fe, iron; Hb, hemoglobin; HIF-α, hypoxia-inducible factor-prolyl-alpha; HIF-β, hypoxia-inducible factor-prolyl-beta; HR, hazard ratio; MACE, major adverse cardiovascular event; MOA, mechanism of action; OH, hydroxl ion; PHD, prolyl-4-hydroxylase domain.

Two JESDUVROQ patients

Could oral JESDUVROQ be right for your appropriate patients?

LEARN ABOUT JAMES AND MARY

Product availability and reimbursement

JESDUVROQ is considered part of a renal dialysis service and is included in the End-Stage Renal Disease (ESRD) Prospective Payment System (PPS). Centers for Medicare & Medicaid Services (CMS) issued Healthcare Common Procedure Coding System (HCPCS) code J0889 for JESDUVROQ and granted a two-year Transitional Drug Add-on Payment Adjustment (TDAPA) period starting October 1, 2023. JESDUVROQ is currently available for purchase through authorized specialty distributors.

JESDUVROQ Ordering Guide

Ordering Guide

Information on how to order JESDUVROQ

SEE ORDERING GUIDE